Glycobiology Advance Access originally published online on January 19, 2007
Glycobiology 2007 17(4):15R-22R; doi:10.1093/glycob/cwm004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
REVIEW |
Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function
Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Otto-Krayer-Haus, Albertstrasse 25, D-79104 Freiburg, Germany
1 To whom correspondence should be addressed; Tel: +49-761-2035301; Fax: +49-761-2035311; E-mail: klaus.aktories{at}pharmakol.uni-freiburg.de
Received on December 8, 2006; revised on January 9, 2007; accepted on January 9, 2007
 |
Abstract |
|---|
Top
Abstract
IntroductionClostridium difficile causes pseudomembranous colitis and is responsible for many cases of nosocomial antibiotic-associated diarrhea. Major virulence factors of C. difficile are the glucosylating exotoxins A and B. Both toxins enter target cells in a pH- dependent manner from endosomes by forming pores. They translocate the N-terminal catalytic domains into the cytosol of host cells and inactivate Rho guanosine triphosphatases by glucosylation. The crystal structure of the catalytic domain of toxin B was solved in a complex with uridine diphosphate, glucose, and manganese ion, exhibiting a folding of type A family glycosyltransferases. Crystallization of fragments of the C-terminus of toxin A, which is characterized by polypeptide repeats, revealed a solenoid-like structure often found in bacterial cell surface proteins. These studies, which provide new insights into structure, uptake, and function of the family of clostridial glucosylating toxins, are reviewed.
Key words:
Bacterial protein toxins
/
clostridial glucosylating toxins
/
glycosyltransferases
/
crystal structure
/
protein toxin uptake
/
Rho proteins
/
UDP-glucose
/
Clostridium novyi 
-toxin
|
Introduction |
|---|
Clostridium difficile is the major cause of pseudomembranous colitis and has recently emerged as the most frequently identified cause of nosocomial antibiotic-associated diarrhea (AAD) in developed countries (Borriello 1998
; Kelly and LaMont 1998; Bartlett 2002). In the United States, annual incidence of AAD are more than three million cases with estimated health care costs exceeding US$1.1 billion (Kyne et al. 2002). C. difficile causes disease by the release of two potent exotoxins, toxin A and toxin B, which induce diarrhea, inflammation, and damage of colonic mucosa (Kelly and LaMont 1998; Voth and Ballard 2005). About 6–10% of C. difficile strains produce besides toxins A and B, a binary actin-adenosine diphosphate (ADP) ribosylating toxin clostridium difficile transferase (CDT) (Perelle et al. 1997). However, the role of this toxin in C. difficile-induced diseases is not clear.
C. difficile toxins A and B belong to the family of large clostridial cytotoxins more appropriately called clostridial glucosylating toxins, because their toxic potency depends on their glucosyltransferase activity (Von Eichel-Streiber et al. 1996; Schirmer and Aktories 2004; Aktories and Barbieri 2005; Aktories and Just 2005; Voth and Ballard 2005). Toxin A consists of 2710 residues (308.0 kDa) and toxin B of 2366 residues (269.6 kDa) (Figure 1). Toxins A and B are encoded by the genes tcdA and tcdB, which are located in a 19.6 kb pathogenicity locus together with three additional genes (tcdC, tcdD, and tcdE) encoding negative (tcdC) and positive (tcdD) regulators as well as a holin-like pore-forming protein (tcdE) (Hammond and Johnson 1995; Hundsberger et al. 1997; Mani and Dupuy 2001). Variations in the structure of the pathogenicity locus (Torres 1991; Rupnik et al. 1997, 1998) are the basis for grouping C. difficile strains in more than 20 toxinotypes. Accordingly, several toxin variants have been reported, especially from toxin B (Rupnik et al. 1998; Chaves-Olarte et al. 1999; Mehlig et al. 2001). Notably, a recently emerging highly virulent C. difficile strain NAP1/027 is characterized by deletion in the tcdC locus by high toxins A and B production and by presence of the binary toxin CDT (McDonald et al. 2005).
|
Quite early, a tripartite structure of the toxins was proposed comprising a biological active N-terminal domain, a middle part with a small hydrophobic stretch possibly involved in toxin translocation, and a C-terminal receptor binding domain (Von Eichel-Streiber et al. 1992
, 1996). This structure model resembles AB toxins, which consist of a biologically active domain, and a binding and translocation domain. |
The C-terminal binding domain of toxins A and B |
|---|
The C-termini of toxins A and B consists of oligopeptide repeats of 21-, 30-, or 50 amino acids residues (Dove et al. 1990
; Von Eichel-Streiber and Sauerborn 1990; Von Eichel-Streiber et al. 1992; Moncrief and Wilkins 2000). Because oligopeptide repeats of C. difficile toxins are similar to the carbohydrate-binding regions of glycosyltransferases from Streptococcus mutans, it was suggested that this toxin part is involved in binding to cell surface carbohydrate structures (Von Eichel-Streiber et al. 1992). Recently, the crystal structure of a fragment of this repetitive structure of the C-terminus of toxin A (toxinotype VI), covering residues 2582–2709, has been solved (Ho et al. 2005; Greco et al. 2006). This analysis showed that the C-terminus of toxin A has a solenoid-like structure, which consists of 32 short repeats with 15–21 residues and seven long repeats with 30 residues (Figure 1). The short and long repeats have a ß-hairpin structure. In short repeats the ß-hairpins are connected by loops of 7–10 amino acid residues. In long repeats 18 residues connect the ß-hairpins. Each hairpin has contact to the neighboring hairpin structure but is rotated by 120° resulting in a screw-like structure. Highly similar to these solenoid-like structure of the C-terminal repeats of toxin A is the pneumococcal virulence factor LytA (Fernandez-Tornero et al. 2001). Solenoid structures are often found in bacterial surface proteins. Their extended surface allows protein–protein or protein–carbohydrate interactions. In line with this hypothesis is the idea that the repetitive units of toxin A bind to cell-surface carbohydrate receptor. In fact, toxin A binds to Gal1-3Galß1-4GlcNAc carbohydrates (Krivan et al. 1986). Also carbohydrate antigens like Lex and Ley (Tucker and Wilkins 1991) components in human milk and carbohydrates from brush border membranes of hamster ileum (Rolfe and Song 1993) have been shown to bind toxin A. However, Teneberg and coworkers (1996) suggested that glycosphingolipids interact with toxin A. Recently, the crystal structure of toxin A was solved in complex with a synthetic carbohydrate consisting of the Gal1-3Galß1-4GlcNAc structure (Greco et al. 2006). This analysis revealed that the carbohydrates bind to a specific region in the C-terminus of toxin A that is formed by long peptide repeats and the hairpin turn of the following short peptide repeat. However, this carbohydrate structure is most likely not part of the intestinal receptors in man, because they do not have a functional -galactosyltransferase and, therefore, cannot form -galactosyl bonds (Koike et al. 2002). Whether other glycans are essential for toxin binding remains to be tested. From the structures available it is feasible that even a weak affinity of a single glycan binding site may increase the binding avidity of the toxin if multivalent binding occurs.
Our knowledge about the cell surface receptor of toxin B receptor is even more scarce. However, experimental data suggest that toxin A and B use different types of receptors. The receptor for toxin B appears to be basolateral located on colon carcinoma T-84 target cells, whereas the receptor for toxin A is on the apical site (Stubbe et al. 2000).
|
Toxins' uptake |
|---|
After binding to their receptors, the toxins are endocytosed (Florin and Thelestam 1983
; Henriques et al. 1987; Barth et al. 2001) (Figure 2). However, the precise endocytic pathway has not been elucidated. Translocation into the cytosol occurs from an acidic endosomal compartment. This was recently verified by using bafilomycin to block the vesicular H+-adenosine triphophatase (Qa'Dan et al. 2000; Barth et al. 2001). Most likely, the low pH of early endosomes causes a conformational change of the protein and the exposure of hydrophobic regions of the toxins, which are previously masked within the protein (Qa'Dan et al. 2000). The crucial role of the low pH of endosomes can be mimicked by short term decrease of the pH of the cell culture medium (Barth et al. 2001). Thus, even in the presence of bafilomycin, which blocks acidification of endosomes, shift of the pH of the medium allows the uptake of toxin A and B. The uptake of the toxins is paralleled by the formation of pores. This was shown by prior loading cells with 86Rb ions. In the presence of toxin B, decrease of the extracellular pH of 86Rb+ loaded cells caused significant outflow of the radioactive cations (Barth et al. 2001). This effect was specifically blocked by addition of antibody against the toxins. An N-terminal deleted mutant of toxin B, comprising the C-terminus and the middle part of toxin B, was sufficient to induce pore formation (Barth et al. 2001). However, the N-terminus of the toxins, which harbors the catalytic domain, was not able to induce or prevent pore formation. The pore-forming effect of toxin A is largely cell type specific (e.g., pore formation occurs in Caco-2 cells but not in Chinese hamster ovary cells) and depends on the presence of cholesterol (Giesemann et al. 2006). Cholesterol depletion of membranes with methyl-beta-cyclodextrin inhibited 86Rb+ efflux and cholesterol repletion reconstituted pore-forming activity of toxin A (Giesemann et al. 2006). Similarly, in black lipid membranes, toxin A induces ion-permeable pores at low pH only in cholesterol-containing bilayers, whereas toxin B forms pores in the absence of cholesterol (Giesemann et al. 2006).
|
The precise mechanism of the toxin translocation is still unclear. Recent studies indicate that the toxins have to be processed to reach the cytosol. It is suggested that only the catalytic domain of toxin B is translocated into the cytosol (Pfeifer et al. 2003
) (Figure 2). The enzyme domain but not other parts of toxin B is detected in the cytosol after treatment of cells with the holotoxin. Moreover, this cytosolic fraction, which contains glucosyltransferase activity and modifies RhoA, does not cause toxin effects when added to naive cells. Thus, the cytosol contains the catalytic domain but not the binding and translocation domains. Rupnik and coworkers (2005) demonstrated that the first 543 amino acids are cleaved to reach the cytosolic fraction. So far it is not clear, where the cleavage occurs and which processes are involved (Rupnik et al. 2005). |
Rho proteins are targets of C. difficile toxins |
|---|
Toxin targets in the cytosol are Rho proteins. Rho proteins are molecular switches involved in numerous signal processes, including actin cytoskeleton regulation, cell cycle progression, gene transcription, and control of the activity of many enzymes like protein and lipid kinases, phospholipases, and nicotanimide adenine dinucleotide-oxidase (Etienne-Manneville and Hall 2002
; Burridge and Wennerberg, 2004). In respect to their role in host–pathogen interactions, Rho proteins essentially participate in epithelial barrier functions and cell–cell contact, in immune cell migration, phagocytosis, cytokine production, wound repair, immune cell signaling, and superoxide anion production (Figure 3). Rho proteins are regulated by a guanosine triphosphatase (GTPase) cycle. They are inactive in the guanosine diphosphate (GDP)-bound form. Activation occurs after GDP/GTP exchange, which is induced by guanine nucleotide exchange factors (GEFs). In the active form, the Rho proteins interact with numerous effectors and adaptors. The active state is terminated by GTP hydrolysis, which is facilitated by GTPase activating proteins (GAPs). In addition, Rho proteins are regulated by guanine nucleotide dissociation inhibitors (GDIs). These proteins keep the inactive form of Rho proteins soluble in the cytosol and appear to be involved in the transport of the Rho proteins to the subcellular compartment, where they are supposed to act.
|
Substrates of toxins A and B are RhoA, B, C, Rac1-3, RhoG, Cdc42, and TC10 but not RhoE or RhoD. All Rho proteins are modified by toxins A and B at the same amino acid residue, which is Thr37 in the case of RhoA and Thr35 in Rac and Cdc42 (Just, Selzer et al. 1995, Just, Wilm et al. 1995). The related C. sordellii lethal toxin and toxin B isoforms (e.g., toxin B 1470), which have a substrate specificity similar to lethal toxin, modify Rac and Ras proteins but not RhoA, also glucosylate Ras proteins at the equivalent position, namely Thr35 (Just et al. 1995a
, 1996; Popoff et al. 1996; Chaves-Olarte et al. 1999). Thr37/35 is highly conserved within the family of small GTPases and essential for nucleotide binding and coordination of the divalent cation magnesium. Moreover, this residue is located in the switch-I region of the GTPase. In this region, major conformational changes occur subsequent to the activation of GDP/GTP exchange (Vetter and Wittinghofer 2001).
Toxin catalyzed modification of Rho and Ras proteins has several functional consequences (Figure 3). First, after glucosylation Rho/Ras proteins are no longer able to interact with their effectors (Herrmann et al. 1998; Sehr et al. 1998). Second, glucosylation inhibits the activation of small GTPases by GEFs (Herrmann et al. 1998; Sehr et al. 1998). Third, glucosylated Rho proteins are associated with the cell membrane and the membrane-cytosol cycle is blocked (Genth et al. 1999). However, the most important structural consequence of glucosylation is probably inhibition of the change into the active conformation of the GTPase. This was shown for glucosylated Ras but so far not for Rho GTPases (Vetter et al. 2000; Geyer et al. 2003). All the above mentioned effects caused by glucosylation of Rho/Ras proteins would inhibit Rho/Ras dependent signaling. A more recent study resulted in a surprising turn in the functional consequences of the action of toxins A and B, because it was observed that the toxins increase the expression of RhoB in target cells (Gerhard et al. 2005). And this effect depends on the glucosyltransferase activity of the toxins. Even more exciting, a large portion of upregulated RhoB remains in the activated state, and is able to escape modification by C. difficile toxins, toxin A or B. This may explain some inflammatory effects of the toxins, which cannot be ascribed solely to Rho-inactivating activity of the glucosyltransferases.
|
Structure of the catalytic domain |
|---|
Recently, the crystal structure of the catalytic domain (residues 1–543) of toxin B, which is translocated into the cytosol of target cells, has been solved (Reinert et al. 2005
). The overall folding of the catalytic core turned out to be a mixed /ß-structure with mostly parallel ß-strands as the central part (Figure 4A). Altogether, the protein fragment consists of 11 ß-strands and 21 -helices. The catalytic core of toxin B consists of 234 residues but possesses more than 300 additional residues. These additional residues are mainly helices. Especially prominent are the 4 N-terminal helices, which appear to be an independent domain. The catalytic core is very similar to other glycosyltransferases like Neisseria meningitidis galatosyltransferase LgtC (Persson et al. 2001), Bacillus subtilis glycosyltransferase SpsA (Charnock and Davies 1999), glycogenin (Gibbons et al. 2002) and bovine galactosyltransferase alpha3GalT (Gastinel et al. 2001), which all belong to type A family of glycosyltransferases (Unligil and Rini 2000; Coutinho et al. 2003; Breton et al. 2006).
|
Although uridine diphosphate (UDP)-glucose, the cosubstrate of clostridial glucosylating toxins, was cleaved during crystallization by the enzyme activity of the catalytic domain, the fact that UDP and glucose were found in the catalytic domain of toxin B allows major insights into the catalytic mechanism and structure–function relationships of the toxin. In addition, Mn2+, which is essential for the enzyme activity, was found in the structure. The catalytic cleft, which binds UDP-glucose is formed by helices
12 and 18, and the connecting loop of ß2/5, ß5/ß6, ß9/ß10, and the loop between ß11 and 21. Previously, the so-called DXD motif was identified to be typical for many type A glycosyltransferases (Busch et al. 1998; Busch and Aktories 2000). The structure of toxin B reveals that DXD (Asp286 and Asp288) is involved in Mn2+, UDP and glucose complexation (Figure 4B and C). Whereas Asp288 binds directly to manganese, the interaction of Asp286 with the cation occurs via a water molecule. Asp286 also interacts with the 3'-hydroxyl group of the UDP-ribose and with the 3'-hydroxyl group of glucose. Therefore, it has major functions in the tight binding of UDP-glucose in the catalytic cleft of the enzyme. In addition, earlier studies showed that tryptophan 102 is essential for enzyme activity (Busch et al. 2000). This residue stabilizes the uracil ring of UDP by aromatic stacking.
So far the roles of the helical subdomains which surround the catalytic core have not been elucidated. Recently, it was shown that the first 18 N-terminal residues of C. sordellii toxin mediate the preferential binding to phosphatidylserine at the intracellular membrane (Mesmin et al. 2004). This binding was important for the glucosylation of Rac and the biological activity of the toxin. Although toxin B does not share the phosphatidylserine binding site with lethal toxin, the domain-like structure of the N-terminal helices are in line with a putative function of the toxins interaction with membranes.
|
Catalytic mechanism and cosubstrate specificity |
|---|
Glycosyltransferases can be classified as either inverting or retaining enzymes depending on conservation of the anomeric configuration of the cosubstrate (UDP-glucose in the case of toxins A and B) (Figure 5). Crystal structure analysis and nuclear magnetic resonance studies of Ras, which was glucosylated by C. sordellii lethal toxin, proposed that the modification of the GTPases by clostridial glucosylating toxins results in an
-anomeric configuration of the attached glucose, indicating that the toxins are retaining glucosyltransferases (Vetter et al. 2000; Geyer et al. 2003). Two possibilities are discussed for the molecular mechanism: a double displacement reaction that involves formation and subsequent breakdown of a covalent intermediate is one possibility (Davies 2001). For this reaction a nucleophile is required, which must be in the vicinity of the C1 position of the glucose to form a ß-anomeric intermediate. Subsequently, a general base is responsible for the deprotonation of the reactive hydroxyl group of the protein substrate to allow the second SN2 reaction on the C1 carbon, which then retains the original -linkage of the glucose. However, in the structure of toxin B no nucleophile that can attack the ß-site of C1 was found in the appropriate position. Therefore, a SNi (internal return) mechanism has been suggested. This mechanism is characterized by a short-lived oxocarbenium-like intermediate. Recent studies with the oxocarbenium intermediate inhibitor gluconolactone support this view (Geyer et al. 2003).
|
Various clostridial glucosylating toxins mainly differ in their protein substrate specificity. However, the
-toxin from Clostridium novyi differs in its cosubstrate specificity. Whereas -toxin accepts UDP-N-acetylglucosamine (UDP-GlcNAc) as a cosubstrate (Selzer et al. 1996), all the other toxins use UDP-glucose. The crystal structure of toxin B was the first hint to explain this difference (Figure 6). Ile-383 and Glu-385 of toxin B are replaced by serine and alanine in -toxin. These residues appear to limit the space of the catalytic cleft for binding of the cosubstrate. Exchange of these residues also changes the cosubstrate specificities of the toxins. Thus, the toxin B double mutant Ile383Ser and Gln385Ala accepts UDP-GlcNAc as a cosubstrate and causes N-acetylglucosaminylation of RhoA (Jank et al. 2005). Accordingly, the Km value for UDP-GlcNAc of toxin B decreases by about 40-fold. On the other hand, change of Ser385 and Ala387 to isoleucine and glutamine, respectively, turns -toxin into a UDP-glucose accepting transferase.
|
|
Conclusion |
|---|
The structural data for the N-terminus of toxin B and the C-terminus of toxin A, which are now available, allow novel insights into the architecture of the catalytic core and the binding domain of the toxins. These data mean a big step forward in understanding the structure–function relationship and the mode of action of the entire family of clostridial glucosylating toxins. Results from crystal structure analyses may have major impact for the identification of compounds, which are capable of inhibiting the catalytic activity of the toxins or the binding of toxins to their target membranes. Those compounds would be of high value for the development of novel therapeutic drugs for treatment of toxin-induced pseudomembranous colitis or antibiotics-associated diarrhea. However, the complete structure of the toxins is not yet available. Most likely, elucidation of the role and function of the enigmatic middle part of the toxins will provide us with new excitements and many surprises. In addition, solid data on the nature of the toxins' receptors are urgently required for further understanding of the mode of action of this important family of protein toxins.
|
Conflict of interest statement |
|---|
None declared.
|
Abbreviations |
|---|
AAD, antibiotic-associated diarrhea; ADP, adenosine diphosphate; CDT, clostridium difficile transferase; GAP, GTPase activating proteins; GDI, guanine nucleotide dissociation inhibitors; GEF, guanine nucleotide exchange factor; GTP, guanosine triphosphate; UDP, uridine diphosphate; UDP-GlcNAc, UDP-N-acetylglucosamine
|
References |
|---|
Aktories K and Barbieri JT. (2005) Bacterial cytotoxins: targeting eukaryotic switches. Nat Rev Microbiol 3:397–410.[CrossRef][ISI][Medline]
Aktories K and Just I. (2005) Clostridial Rho-inhibiting protein toxins. Curr Top Microbiol Immunol 291:113–145.[ISI][Medline]
Barth H, Pfeifer G, Hofmann F, Maier E, Benz R, Aktories K. (2001) Low pH-induced formation of ion channels by Clostridium difficile toxin B in target cells. J Biol Chem 276:10670–10676.
Bartlett JG. (2002) Clinical practice: antibiotic-associated diarrhea. N Engl J Med 346:334–339.
Borriello SP. (1998) Pathogenesis of Clostridium difficile infection. J Antimicrob Chemother 41:13–19.
Breton C, Snajdrova L, Jeanneau C, Koca J, Imberty A. (2006) Structures and mechanisms of glycosyltransferases. Glycobiology 16:.
Burridge K and Wennerberg K. (2004) Rho and Rac take center stage. Cell 116:167–179.[CrossRef][ISI][Medline]
Busch C and Aktories K. (2000) Microbial toxins and the glucosylation of Rho family GTPases. Curr Opin Struct Biol 10:528–535.[CrossRef][ISI][Medline]
Busch C, Hofmann F, Gerhard R, Aktories K. (2000) Involvement of a conserved tryptophan residue in the UDP-glucose binding of large clostridial cytotoxin glycosyltransferases. J Biol Chem 275:13228–13234.
Busch C, Hofmann F, Selzer J, Munro J, Jeckel D, Aktories K. (1998) A common motif of eukaryotic glycosyltransferases is essential for the enzyme activity of large clostridial cytotoxins. J Biol Chem 273:19566–19572.
Charnock SJ and Davies GJ. (1999) Structure of the nucleotide-diphospho-sugar transferase, SpsA from Bacillus subtilis, in native and nucleotide-complexed forms. Biochemistry 38:6380–6385.[CrossRef][Medline]
Chaves-Olarte E, Löw P, Freer E, Norlin T, Weidmann M, Von Eichel-Streiber C, Thelestam M. (1999) A novel cytotoxin from Clostridium difficile serogroup F is a functional hybrid between two other large clostridial cytotoxins. J Biol Chem 274:11046–11052.
Coutinho PM, Deleury E, Davies GJ, Henrissat B. (2003) An evolving hierarchical family classification for glycosyltransferases. J Mol Biol 328:307–317.[CrossRef][ISI][Medline]
Davies GJ. (2001) Sweet secrets of synthesis. Nat Struct Biol 8:98–100.[CrossRef][ISI][Medline]
Dove CH, Wang SZ, Price SB, Phelps CJ, Lyerly DM, Wilkins TD, Johnson JL. (1990) Molecular characterization of the Clostridium difficile toxin A gene. Infect Immun 58:480–488.
Etienne-Manneville S and Hall A. (2002) Rho GTPases in cell biology. Nature 420:629–635.[CrossRef][Medline]
Fernandez-Tornero C, Lopez R, Garcia E, Gimenez-Gallego G, Romero A. (2001) A novel solenoid fold in the cell wall anchoring domain of the pneumococcal virulence factor LytA. Nat Struct Biol 8:1020–1024.[CrossRef][ISI][Medline]
Florin I and Thelestam M. (1983) Internalization of Clostridium difficile cytotoxin into cultured human lung fibroblasts. Biochim Biophys Acta 763:383–392.[Medline]
Gastinel LN, Bignon C, Misra AK, Hindsgaul O, Shaper JH, Joziasse DH. (2001) Bovine alpha1,3-galactosyltransferase catalytic domain structure and its relationship with ABO histo-blood group and glycosphingolipid glycosyltransferases. EMBO J 20:638–649.[CrossRef][ISI][Medline]
Genth H, Aktories K, Just I. (1999) Monoglucosylation of RhoA at Threonine-37 blocks cytosol-membrane cycling. J Biol Chem 274:29050–29056.
Gerhard R, Tatge H, Genth H, Thum T, Borlak J, Fritz G, Just I. (2005) Clostridium difficile toxin A induces expression of the stress-induced early gene product RhoB. J Biol Chem 280:1499–1505.
Geyer M, Wilde C, Selzer J, Aktories K, Kalbitzer HR. (2003) Glucosylation of Ras by Clostridium sordellii lethal toxin: consequences for the effector loop conformations observed by NMR spectroscopy. Biochemistry 42:11951–11959.[CrossRef][Medline]
Gibbons BJ, Roach PJ, Hurley TD. (2002) Crystal structure of the autocatalytic initiator of glycogen biosynthesis, glycogenin. J Mol Biol 319:463–477.[CrossRef][ISI][Medline]
Giesemann T, Jank T, Gerhard R, Maier E, Just I, Benz R, Aktories K. (2006) Cholesterol-dependent pore formation of Clostridium difficile toxin A. J Biol Chem 281:10808–10815.
Greco A, Ho JG, Lin SJ, Palcic MM, Rupnik M, Ng KK. (2006) Carbohydrate recognition by Clostridium difficile toxin A. Nat Struct Mol Biol. 13:460–461.[CrossRef][ISI][Medline]
Hammond GA and Johnson JL. (1995) The toxigenic element of Clostridium difficile strain VPI 10463. Microb Pathog 19:203–213.[CrossRef][ISI][Medline]
Henriques B, Florin I, Thelestam M. (1987) Cellular internalisation of Clostridium difficile toxin A. Microb Pathog 2:455–463.[CrossRef][ISI][Medline]
Herrmann C, Ahmadian MR, Hofmann F, Just I. (1998) Functional consequences of monoglucosylation of H-Ras at effector domain amino acid threonine-35. J Biol Chem 273:16134–16139.
Ho JG, Greco A, Rupnik M, Ng KK. (2005) Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A. Proc Natl Acad Sci USA 102:18373–18378.
Hundsberger T, Braun V, Weidmann M, Leukel P, Sauerborn M, Von Eichel-Streiber C. (1997) Transcription analysis of the genes tcdA-E of the pathogenicity locus of Clostridium difficile. Eur J Biochem 244:735–742.[ISI][Medline]
Jank T, Reinert DJ, Giesemann T, Schulz GE, Aktories K. (2005) Change of the donor substrate specificity of Clostridium difficile toxin B by site-directed mutagenesis. J Biol Chem 280:37833–37838.
Just I, Selzer J, Hofmann F, Green GA, Aktories K. (1996) Inactivation of Ras by Clostridium sordellii lethal toxin-catalyzed glucosylation. J Biol Chem 271:10149–10153.
Just I, Selzer J, Wilm M, Von Eichel-Streiber C, Mann M, Aktories K. (1995a) Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature 375:500–503.[CrossRef][Medline]
Just I, Wilm M, Selzer J, Rex G, Von Eichel-Streiber C, Mann M, Aktories K. (1995b) The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins. J Biol Chem 270:13932–13936.
Kelly CP and LaMont JT. (1998) Clostridium difficile infection. Annu Rev Med 49:375–390.[CrossRef][ISI][Medline]
Koike C, Fung JJ, Geller DA, Kannagi R, Libert T, Luppi P, Nakashima I, Profozich J, Rudert W, Sharma SB, Starzl TE, Trucco M. (2002) Molecular basis of evolutionary loss of the alpha 1,3-galactosyltransferase gene in higher primates. J Biol Chem 277:10114–10120.
Krivan HC, Clark GF, Smith DF, Wilkins TD. (1986) Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal1-3Galß1-4GlcNAc. Infect Immun 53:573–581.
Kyne L, Hamel MB, Polavaram R, Kelly CP. (2002) Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 34:346–353.[CrossRef][ISI][Medline]
Mani N and Dupuy B. (2001) Regulation of toxin synthesis in Clostridium difficile by an alternative RNA polymerase sigma factor. Proc Natl Acad Sci USA 98:5844–5849.
McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, Johnson S, Gerding DN. (2005) An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353:2433–2441.
Mehlig M, Moos M, Braun V, Kalt B, Mahony DE, Von Eichel-Streiber C. (2001) Variant toxin B and a functional toxin A produced by Clostridium difficile C34. FEMS Microbiol Lett 198:171–176.[CrossRef][ISI][Medline]
Mesmin B, Robbe K, Geny B, Luton F, Brandolin G, Popoff MR, Antonny B. (2004) A phosphatidylserine-binding site in the cytosolic fragment of Clostridium sordellii lethal toxin facilitates glucosylation of membrane-bound Rac and is required for cytotoxicity. J Biol Chem 279:49876–49882.
Moncrief JS and Wilkins TD. (2000) Genetics of Clostridium difficile toxins. Curr Top Microbiol Immunol 250:35–54.[ISI][Medline]
Perelle S, Gibert M, bourlioux P, Corthier G, Popoff MR. (1997) Production of a complete binary toxin (actin-specific ADP-ribosyltransferase) by Clostridium difficile CD196. Infect Immun 65:1402–1407.[Abstract]
Persson K, Ly HD, Dieckelmann M, Wakarchuk WW, Withers SG, Strynadka NC. (2001) Crystal structure of the retaining galactosyltransferase LgtC from Neisseria meningitidis in complex with donor and acceptor sugar analogs. Nat Struct Biol 8:166–175.[CrossRef][ISI][Medline]
Pfeifer G, Schirmer J, Leemhuis J, Busch C, Meyer DK, Aktories K, Barth H. (2003) Cellular uptake of Clostridium difficile toxin B: translocation of the N-terminal catalytic domain into the cytosol of eukaryotic cells. J Biol Chem 278:44535–44541.
Popoff MR, Chaves-Olarte E, Lemichez E, von Eichel-Streiber C, Thelestam M, Chardin P, Cussac D, Antonny B, Chavrier P, Flatau G, Giry M, de Gunzburg J, Boquet P. (1996) Ras, Rap, and Rac small GTP-binding proteins are targets for Clostridium sordellii lethal toxin glucosylation. J Biol Chem 271:10217–10224.
Qa'Dan M, Spyres LM, Ballard JD. (2000) pH-induced conformational changes in Clostridium difficile toxin B. Infect Immun 68:2470–2474.
Reinert DJ, Jank T, Aktories K, Schulz GE. (2005) Structural basis for the function of Clostridium difficile toxin B. J Mol Biol 351:973–981.[CrossRef][ISI][Medline]
Rolfe RD and Song W. (1993) Purification of a functional receptor for Clostridium difficile toxin A from intestinal brush border membranes of infant hamsters. Clin Infect Dis 16:219–227.[ISI][Medline]
Rupnik M, Avesani V, Janc M, Von Eichel-Streiber C, Delmée M. (1998) A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol 36:2240–2247.
Rupnik M, Braun V, Soehn F, Janc M, Hofstetter M, Laufenberg-Feldmann R, Von Eichel-Streiber C. (1997) Characterization of polymorphisms in the toxin A and B genes of Clostridium difficile. FEMS Microbiol Lett 148:197–202.[CrossRef][ISI][Medline]
Rupnik M, Pabst S, Rupnik M, Von Eichel-Streiber C, Urlaub H, Soling HD. (2005) Characterization of the cleavage site and function of resulting cleavage fragments after limited proteolysis of Clostridium difficile toxin B (TcdB) by host cells. Microbiology 151:199–208.
Schirmer J and Aktories K. (2004) Large clostridial cytotoxins: cellular biology of Rho/Ras-glucosylating toxins. Biochim Biophys Acta 1673:66–74.[Medline]
Sehr P, Joseph G, Genth H, Just I, Pick E, Aktories K. (1998) Glucosylation and ADP-ribosylation of Rho proteins—effects on nucleotide binding, GTPase activity, and effector-coupling. Biochemistry 37:5296–5304.[CrossRef][Medline]
Selzer J, Hofmann F, Rex G, Wilm M, Mann M, Just I, Aktories K. (1996) Clostridium novyi -toxin-catalyzed incorporation of GlcNAc into Rho subfamily proteins. J Biol Chem 271:25173–25177.
Stubbe H, Berdoz J, Kraehenbuhl J-P, Corthésy B. (2000) Polymeric IgA is superior to monomeric IgA and IgG carrying the same variable domain in preventing Clostridium difficile toxin A damaging of T84 monolayers. J Immunol 164:1952–1960.
Teneberg S, Lönnroth I, López JFT, Galili U, Halvarsson MÖ, Ångström J, Karlsson KA. (1996) Molecular mimicry in the recognition of glycosphingolipids by Gal3Galß4GlcNAcß-binding Clostridium difficile toxin A, human natural anti -galactosyl IgG and the monoclonal antibody Gal-13: characterization of a binding-active human glycosphingolipid, non- identical with the animal receptor. Glycobiology 6:599–609.
Torres JF. (1991) Purification and characterisation of toxin B from a strain of Clostridium difficile that does not produce toxin A. J Med Microbiol 35:40–44.[Abstract]
Tucker KD and Wilkins TD. (1991) Toxin A of Clostridium difficile binds to the human carbohydrate antigens I, X, and Y. Infect Immun 59:73–78.
Unligil UM and Rini JM. (2000) Glycosyltransferase structure and mechanism. Curr Opin Struct Biol 10:510–517.[CrossRef][ISI][Medline]
Vetter IR, Hofmann F, Wohlgemuth S, Herrmann C, Just I. (2000) Structural consequences of mono-glucosylation of Ha-Ras by Clostridium sordellii lethal toxin. J Mol Biol 301:1091–1095.[CrossRef][ISI][Medline]
Vetter IR and Wittinghofer A. (2001) The guanine nucleotide-binding switch in three dimensions. Science 294:1299–1304.
Von Eichel-Streiber C, Boquet P, Sauerborn M, Thelestam M. (1996) Large clostridial cytotoxins—a family of glycosyltransferases modifying small GTP-binding proteins. Trends Microbiol 4:375–382.[CrossRef][ISI][Medline]
Von Eichel-Streiber C and Sauerborn M. (1990) Clostridium difficile toxin A carries a C-terminal structure homologous to the carbohydrate binding region of streptococcal glycosyltransferase. Gene 96:107–113.[CrossRef][ISI][Medline]
Von Eichel-Streiber C, Sauerborn M, Kuramitsu HK. (1992) Evidence for a modular structure of the homologous repetitive C-terminal carbohydrate-binding sites of Clostridium difficile toxins and streptcoccus mutans glucosyltransferases. J Bacteriol 174:6707–6710.
Voth DE and Ballard JD. (2005) Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 18:247–263.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Giesemann, M. Egerer, T. Jank, and K. Aktories Processing of Clostridium difficile toxins J. Med. Microbiol., June 1, 2008; 57(6): 690 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. BRUGGEMANN and G. GOTTSCHALK Comparative Genomics of Clostridia: Link between the Ecological Niche and Cell Surface Properties Ann. N.Y. Acad. Sci., March 1, 2008; 1125(1): 73 - 81. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Egerer, T. Giesemann, T. Jank, K. J. F. Satchell, and K. Aktories Auto-catalytic Cleavage of Clostridium difficile Toxins A and B Depends on Cysteine Protease Activity J. Biol. Chem., August 31, 2007; 282(35): 25314 - 25321. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||